Literature DB >> 27549098

Discovery and Development of Topoisomerase Inhibitors as Anticancer Agents.

Muthu K Kathiravan1, Anuj N Kale, Shrikant Nilewar.   

Abstract

As one of the leading causes of deaths worldwide, cancer is posing threat despite efforts being taken to develop effective anticancer drugs. There is an increase in number of chemotherapy treatments due to growing number of manifestations causing increasing toxicities of cytotoxic agents. Almost all the anticancer agents available till date have one or the other side effects. Topoisomerases are the attractive targets to develop effective anticancer agents. There has been development of many topoisomerase inhibitors till date and has shown good anticancer activity but their side effects outnumber their anticancer potential. Hence, there is an urgent need to develop effective therapeutic agents with fewer side effects. This review deals with design and development aspect of topoisomerase inhibitors as exciting novel anticancer agents. The emphasis has been laid in particular on the new potential heterocyles as TOP inhibitors in the field of medicinal chemistry. The review discusses about the topoisomerase poisons, TOP1 suppressors, TOP inhibitors and Dual TOP 1/2 inhibitors.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27549098     DOI: 10.2174/1389557516666160822110819

Source DB:  PubMed          Journal:  Mini Rev Med Chem        ISSN: 1389-5575            Impact factor:   3.862


  8 in total

Review 1.  Chromatin dependencies in cancer and inflammation.

Authors:  Ivan Marazzi; Benjamin D Greenbaum; Diana H P Low; Ernesto Guccione
Journal:  Nat Rev Mol Cell Biol       Date:  2017-11-29       Impact factor: 94.444

Review 2.  Polymer-Drug Conjugate, a Potential Therapeutic to Combat Breast and Lung Cancer.

Authors:  Sibusiso Alven; Xhamla Nqoro; Buhle Buyana; Blessing A Aderibigbe
Journal:  Pharmaceutics       Date:  2020-04-29       Impact factor: 6.321

3.  Preparation of Enzyme-Activated Thapsigargin Prodrugs by Solid-Phase Synthesis.

Authors:  Tomas Zimmermann; Søren Brøgger Christensen; Henrik Franzyk
Journal:  Molecules       Date:  2018-06-15       Impact factor: 4.411

4.  Study on the expression of TOP2A in hepatocellular carcinoma and its relationship with patient prognosis.

Authors:  Jiali Meng; Yuanchao Wei; Qing Deng; Ling Li; Xiaolong Li
Journal:  Cancer Cell Int       Date:  2022-01-15       Impact factor: 5.722

5.  Implications of Topoisomerase (TOP1 and TOP2α) Expression in Patients With Breast Cancer.

Authors:  Misato Ogino; Takaaki Fujii; Yuko Nakazawa; Toru Higuchi; Yukio Koibuchi; Tetsunari Oyama; Jun Horiguchi; Ken Shirabe
Journal:  In Vivo       Date:  2020 Nov-Dec       Impact factor: 2.155

6.  Synthesis, anticancer evaluation and molecular docking studies of new benzimidazole- 1,3,4-oxadiazole derivatives as human topoisomerase types I poison.

Authors:  Ulviye Acar Çevik; Begüm Nurpelin Sağlık; Derya Osmaniye; Serkan Levent; Betül Kaya Çavuşoğlu; Abdullah Burak Karaduman; Özlem Atlıd; Özlem Atlı Eklioğlu; Zafer Asım Kaplancıklı
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051

7.  DNA topoisomerase 1 and 2A function as oncogenes in liver cancer and may be direct targets of nitidine chloride.

Authors:  Li-Min Liu; Dan-Dan Xiong; Peng Lin; Hong Yang; Yi-Wu Dang; Gang Chen
Journal:  Int J Oncol       Date:  2018-08-21       Impact factor: 5.650

8.  Zanthoxylum zanthoxyloides Alkaloidal Extract Improves CCl4-Induced Hepatocellular Carcinoma-Like Phenotypes in Rats.

Authors:  Desmond Omane Acheampong; Isaac Kyei Baffour; Victor Yao Atsu Barku; Justice Kwaku Addo; Mainprice Akuoko Essuman; Alex Boye
Journal:  Evid Based Complement Alternat Med       Date:  2021-07-21       Impact factor: 2.629

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.